Gene: AKT3

10000
MPPH|MPPH2|PKB-GAMMA|PKBG|PRKBG|RAC-PK-gamma|RAC-gamma|STK-2
AKT serine/threonine kinase 3
protein-coding
1q43-q44
Ensembl:ENSG00000117020 MIM:611223 Vega:OTTHUMG00000039994 UniprotKB:Q9Y243
NG_029764.1
PubMed
ND
4   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.721e-2 (AD)  2.442e-1 (ND)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg11496569chr1:244006397AKT31.400e-12Smoking27651444
cg11314684chr1:244006288AKT33.000e-12Smoking27651444
cg04221461chr1:243877024AKT34.000e-9Smoking27651444

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
MYCBP20.97
OXR10.966
ZFYVE90.963
GSK3B0.96
ADAM220.959
RAPGEF20.957
PIK3CB0.956
SATB10.956
HIVEP20.955
SRPK20.955

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.475
RAB13-0.475
HEY2-0.464
CSAG1-0.464
OR4F29-0.456
MYL3-0.45
TMEM102-0.449
RNF135-0.447
ROM1-0.445
FLT3LG-0.441

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5486512-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in decreased expression of AKT3 mRNA19933214
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AKT3 mRNA"25510870
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AKT3 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"2,4,5,2',4',5'-hexachlorobiphenyl affects the expression of AKT3 mRNA"20638727
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AKT3 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AKT3 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AKT3 mRNA"25510870
C0212962-ethoxyethanol2-ethoxyethanol results in increased expression of AKT3 mRNA19643169
C0087454,4'-bisphenol F"4,4'-bisphenol F results in decreased expression of AKT3 mRNA"26186136
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKT3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with methylmercuric chloride co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKT3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKT3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKT3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with methylmercuric chloride co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKT3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKT3 mRNA"27188386
D000082AcetaminophenAcetaminophen results in increased expression of AKT3 mRNA29067470
D000643Ammonium ChlorideAmmonium Chloride affects the expression of AKT3 mRNA16483693
D001151ArsenicArsenic affects the methylation of AKT3 gene25304211
C015001arsenitearsenite results in decreased expression of AKT3 mRNA23974009
C547126AZM551248AZM551248 results in increased expression of AKT3 mRNA22323515
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of AKT3 mRNA22228805
C006780bisphenol Abisphenol A results in decreased expression of AKT3 mRNA29275510
C006780bisphenol A[bisphenol A co-treated with Genistein] results in increased expression of AKT3 protein24884420
C006780bisphenol Abisphenol A results in decreased expression of AKT3 mRNA25181051
C006780bisphenol Abisphenol A results in increased expression of AKT3 protein24884420
C006780bisphenol Abisphenol A results in increased methylation of AKT3 gene28505145
C018475butyraldehydebutyraldehyde results in decreased expression of AKT3 mRNA26079696
D019256Cadmium ChlorideCadmium Chloride results in decreased expression of AKT3 mRNA26472689
C054133casticincasticin results in decreased expression of AKT3 mRNA27862857
D002976ClenbuterolClenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein]16339297
C018021cobaltous chloridecobaltous chloride results in decreased expression of AKT3 mRNA19320972
D005576ColforsinColforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein]16339297
C057862cyanoginosin LRcyanoginosin LR results in decreased expression of AKT3 mRNA28414124
C057862cyanoginosin LRcyanoginosin LR results in decreased expression of AKT3 protein28414124
D016572CyclosporineCyclosporine results in increased expression of AKT3 mRNA20106945
C010902decabromobiphenyl etherdecabromobiphenyl ether results in decreased expression of AKT3 mRNA23640034
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in decreased expression of AKT3 mRNA27392435
D002945CisplatinCisplatin results in decreased expression of AKT3 mRNA27392435
D004280DobutamineDobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein]16339297
D004317DoxorubicinAKT3 protein affects the susceptibility to Doxorubicin18071906
C118739entinostatentinostat results in decreased expression of AKT3 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKT3 mRNA"27188386
C045651epigallocatechin gallate[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AKT3 mRNA22079256
D005557FormaldehydeFormaldehyde results in decreased expression of AKT3 mRNA23649840
C001277geldanamycingeldanamycin results in increased expression of AKT3 mRNA26705709
D019833Genistein[bisphenol A co-treated with Genistein] results in increased expression of AKT3 protein24884420
D017313FenretinideFenretinide results in increased expression of AKT3 mRNA28973697
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of AKT3 mRNA25613284
C544151jinfukang[Cisplatin co-treated with jinfukang] results in decreased expression of AKT3 mRNA27392435
D007854LeadLead results in increased expression of AKT3 mRNA19921347
C005219methyl cellosolvemethyl cellosolve results in increased expression of AKT3 mRNA19643169
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of AKT3 mRNA26272509
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of AKT3 mRNA28001369
C004925methylmercuric chloride"[NOG protein co-treated with methylmercuric chloride co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKT3 mRNA"27188386
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of AKT3 mRNA23649840
C056218ML 9ML 9 inhibits the reaction [FGF1 protein alternative form results in increased phosphorylation of AKT3 protein]15517595
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of AKT3 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of AKT3 mRNA"25554681
D016627OxidopamineClenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein]16339297
D016627OxidopamineColforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein]16339297
D016627OxidopamineDobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein]16339297
D016627OxidopamineOxidopamine results in decreased phosphorylation of AKT3 protein16339297
D017239PaclitaxelAKT3 protein affects the susceptibility to Paclitaxel18071906
D052638Particulate MatterParticulate Matter results in decreased expression of AKT3 mRNA28412507
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AKT3 mRNA"25510870
C027373potassium chromate(VI)[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AKT3 mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in decreased expression of AKT3 mRNA22079256|2271453
D011441PropylthiouracilPropylthiouracil results in increased expression of AKT3 mRNA20951798
C059514resveratrolresveratrol results in decreased expression of AKT3 mRNA25667456
C009277sodium arsenatesodium arsenate results in increased expression of AKT3 mRNA21795629
C017947sodium arsenitesodium arsenite affects the methylation of AKT3 gene28589171
C017947sodium arsenitesodium arsenite results in decreased expression of and affects the splicing of AKT3 mRNA25879800
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of AKT3 mRNA21570461
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of AKT3 mRNA25613284
D013849ThimerosalThimerosal results in decreased expression of AKT3 mRNA27188386
D019772TopotecanAKT3 protein affects the susceptibility to Topotecan16217747
C483909torcetrapibtorcetrapib results in increased expression of AKT3 mRNA23228038
D014212TretinoinTretinoin results in increased expression of AKT3 mRNA23724009
D014241TrichloroethyleneTrichloroethylene results in decreased methylation of AKT3 gene27618143
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKT3 mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of AKT3 mRNA24935251|2627250
D014635Valproic AcidValproic Acid results in decreased expression of AKT3 mRNA23179753
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of AKT3 gene25560391
C111237vorinostatvorinostat results in decreased expression of AKT3 mRNA27188386
D015032ZincZinc deficiency results in decreased expression of AKT3 mRNA20857495

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004672protein kinase activity-TAS10092583  
GO:0004674protein serine/threonine kinase activity-IBA21873635  
GO:0004674protein serine/threonine kinase activity-IDA16540465  
GO:0005515protein binding-IPI12176997  17544405  19713527  20059950  25036637  25241761  
GO:0005524ATP binding-IDA16540465  
GO ID GO Term Qualifier Evidence PubMed
GO:0000002mitochondrial genome maintenance-IMP18524868  
GO:0001938positive regulation of endothelial cell proliferation-IMP25323119  
GO:0006468protein phosphorylation-TAS10092583  
GO:0007165signal transduction-IMP18524868  
GO:0018105peptidyl-serine phosphorylation-IBA21873635  
GO:0032008positive regulation of TOR signaling-IEA-  
GO:0035556intracellular signal transduction-IBA21873635  
GO:0043536positive regulation of blood vessel endothelial cell migration-IDA28254819  
GO:0045793positive regulation of cell size-IEA-  
GO:0048854brain morphogenesis-IEA-  
GO:0048873homeostasis of number of cells within a tissue-IEA-  
GO:0090050positive regulation of cell migration involved in sprouting angiogenesis-IMP25323119  
GO:1905564positive regulation of vascular endothelial cell proliferation-IDA28254819  
GO:1905653positive regulation of artery morphogenesis-IEA-  
GO:2000773negative regulation of cellular senescence-IMP25323119  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IEA-  
GO:0005737cytoplasm-IEA-  
GO:0016020membrane-IEA-  
KEGG ID KEGG Term
hsa04010MAPK signaling pathway
hsa04012ErbB signaling pathway
hsa04062Chemokine signaling pathway
hsa04150mTOR signaling pathway
hsa04210Apoptosis
hsa04370VEGF signaling pathway
hsa04380Osteoclast differentiation
hsa04510Focal adhesion
hsa04530Tight junction
hsa04620Toll-like receptor signaling pathway
hsa04630Jak-STAT signaling pathway
hsa04660T cell receptor signaling pathway
hsa04662B cell receptor signaling pathway
hsa04664Fc epsilon RI signaling pathway
hsa04666Fc gamma R-mediated phagocytosis
hsa04722Neurotrophin signaling pathway
hsa04910Insulin signaling pathway
hsa04914Progesterone-mediated oocyte maturation
hsa04920Adipocytokine signaling pathway
hsa04973Carbohydrate digestion and absorption
hsa05142Chagas disease (American trypanosomiasis)
hsa05145Toxoplasmosis
hsa05160Hepatitis C
hsa05200Pathways in cancer
hsa05210Colorectal cancer
hsa05211Renal cell carcinoma
hsa05212Pancreatic cancer
hsa05213Endometrial cancer
hsa05214Glioma
hsa05215Prostate cancer
hsa05218Melanoma
hsa05220Chronic myeloid leukemia
hsa05221Acute myeloid leukemia
hsa05222Small cell lung cancer
hsa05223Non-small cell lung cancer
Reactome ID Reactome Term Evidence
R-HSA-109581ApoptosisIEA
R-HSA-109606Intrinsic Pathway for ApoptosisIEA
R-HSA-111447Activation of BAD and translocation to mitochondria IEA
R-HSA-114452Activation of BH3-only proteinsIEA
R-HSA-1227986Signaling by ERBB2TAS
R-HSA-1257604PIP3 activates AKT signalingTAS
R-HSA-1257604PIP3 activates AKT signalingIEA
R-HSA-1266738Developmental BiologyTAS
R-HSA-1280218Adaptive Immune SystemTAS
R-HSA-1358803Downregulation of ERBB2:ERBB3 signalingTAS
R-HSA-162582Signal TransductionTAS
R-HSA-162582Signal TransductionIEA
R-HSA-1640170Cell CycleTAS
R-HSA-1643685DiseaseTAS
R-HSA-168256Immune SystemTAS
R-HSA-186712Regulation of beta-cell developmentTAS
R-HSA-194138Signaling by VEGFTAS
R-HSA-198323AKT phosphorylates targets in the cytosolTAS
R-HSA-198323AKT phosphorylates targets in the cytosolIEA
R-HSA-198693AKT phosphorylates targets in the nucleusTAS
R-HSA-199418Negative regulation of the PI3K/AKT networkTAS
R-HSA-199991Membrane TraffickingTAS
R-HSA-210745Regulation of gene expression in beta cellsTAS
R-HSA-211163AKT-mediated inactivation of FOXO1ATAS
R-HSA-212436Generic Transcription PathwayTAS
R-HSA-212436Generic Transcription PathwayIEA
R-HSA-2219528PI3K/AKT Signaling in CancerTAS
R-HSA-3700989Transcriptional Regulation by TP53TAS
R-HSA-372790Signaling by GPCRTAS
R-HSA-388396GPCR downstream signallingTAS
R-HSA-388841Costimulation by the CD28 familyTAS
R-HSA-389356CD28 co-stimulationTAS
R-HSA-389357CD28 dependent PI3K/Akt signalingTAS
R-HSA-389513CTLA4 inhibitory signalingTAS
R-HSA-392451G beta:gamma signalling through PI3KgammaTAS
R-HSA-397795G-protein beta:gamma signallingTAS
R-HSA-4420097VEGFA-VEGFR2 PathwayTAS
R-HSA-453279Mitotic G1-G1/S phasesTAS
R-HSA-5218920VEGFR2 mediated vascular permeabilityTAS
R-HSA-5357801Programmed Cell DeathIEA
R-HSA-5628897TP53 Regulates Metabolic GenesTAS
R-HSA-5633007Regulation of TP53 ActivityTAS
R-HSA-5653656Vesicle-mediated transportTAS
R-HSA-5663202Diseases of signal transductionTAS
R-HSA-5674400Constitutive Signaling by AKT1 E17K in CancerTAS
R-HSA-6804757Regulation of TP53 DegradationTAS
R-HSA-6804758Regulation of TP53 Activity through AcetylationTAS
R-HSA-6804759Regulation of TP53 Activity through Association with Co-factorsTAS
R-HSA-6806003Regulation of TP53 Expression and DegradationTAS
R-HSA-6807070PTEN RegulationTAS
R-HSA-69202Cyclin E associated events during G1/S transition TAS
R-HSA-69206G1/S TransitionTAS
R-HSA-69242S PhaseTAS
R-HSA-69278Cell Cycle, MitoticTAS
R-HSA-69656Cyclin A:Cdk2-associated events at S phase entryTAS
R-HSA-73857RNA Polymerase II TranscriptionTAS
R-HSA-73857RNA Polymerase II TranscriptionIEA
R-HSA-74160Gene expression (Transcription)TAS
R-HSA-74160Gene expression (Transcription)IEA
R-HSA-8863795Downregulation of ERBB2 signalingTAS
R-HSA-8876198RAB GEFs exchange GTP for GDP on RABsTAS
R-HSA-8878166Transcriptional regulation by RUNX2IEA
R-HSA-8941332RUNX2 regulates genes involved in cell migrationIEA
R-HSA-8948751Regulation of PTEN stability and activityTAS
R-HSA-9006925Intracellular signaling by second messengersTAS
R-HSA-9006925Intracellular signaling by second messengersIEA
R-HSA-9006934Signaling by Receptor Tyrosine KinasesTAS
R-HSA-9007101Rab regulation of traffickingTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
23802852Lung adenocarcinoma biomarker incidence in Hispanic versus non-Hispanic white patients. (2014 Mar)McQuitty EArch Pathol Lab Med
21242979Akt1 deletion prevents lung tumorigenesis by mutant K-ras. (2011 Apr 14)Hollander MCOncogene
25122428Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis. (2014 Sep)Umemura SJ Thorac Oncol
28500316Establishment of a Strong Link Between Smoking and Cancer Pathogenesis through DNA Methylation Analysis. (2017 May 12)Ma YSci Rep